Corcept's Korlym approved by FDA for Cushing's syndrome

Corcept Therapeutic Inc.’s Korlym was approved Friday by the Food and Drug Administration for patients with the orphan disease Cushing’s syndrome.
The agency said the drug can be used to control high blood sugar levels in adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or have not responded to prior surgery.
Korlym was developed by Menlo Park-based Corcept (NASDAQ: CORT).